Uncategorized
Health Canada accepts new drug submission for Iluvien for DME
A new drug submission for Iluvien has been accepted for review by Health Canada, according to a press release from Knight Therapeutics and Alimera Sciences.Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg, Alimera) sustained-release intravitreal implant is already approved in the U.S. to treat diabetic macular edema in patients who were previously treated with corticosteroids.